Oral contraceptives combined with interferon b in multiple sclerosis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 4, 2015, Pages

  Pozzilli, Carlo ^a,b   De Giglio, Laura ^a,b   Barletta, Valeria T ^b   Marinelli, Fabiana ^b   De Angelis, Floriana ^a   Gallo, Valentina ^c   Pagano, Veronica A ^d   Marini, Stefano ^d   Piattella, Maria C ^a   Tomassini, Valentina ^a,e,f,g   Pantano, Patrizia ^a,h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d TFS Trial Form Support SL   (Italy)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^g IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^h IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; DESOGESTREL; ETHINYLESTRADIOL; GADOLINIUM; METHYLPREDNISOLONE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL OUTCOME; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 84991473651     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000120     Document Type: Article

References (29)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502-1517.
2. Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 2008; 28: 17-28.
3. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 1993; 43: 655-661.
4. Jacobs LD, Cookfair DL, Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-294.
5. PRISMS Study Group. Randomised double-blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-1504.
6. Amato MP, Portaccio E, Ghezzi A., et al. Pregnancy and fetal outcomes after interferon-b exposure in multiple sclerosis. Neurology 2010; 75:1794-1802.
7. Voskuhl R, Palazynski K. Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist 2001; 7:258-270.
8. Tomassini V, Pozzilli C. Sex hormone, brain damage and clinical course of MS. J Neurol Sci 2009; 286:35-39.
9. Sicotte NL, Liva SM, Klutch R, et al Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002; 52:421-428.
10. Alonso A, Clark CJ Oral contraceptives and the risk of multiple sclerosis: a review of the epidemiologic evidence. J Neurol Sci 2009; 286:73-75.
11. Holmqvist P, Hammar M, Landtblom A.M., Brynhildsen J. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril 2010; 94:2835-2837.
12. Sena A, Couderc R, Vasconcelos J.C., Ferret-Sena V, Pedrosa RJ. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci 2012; 317: 47-51.
13. D'hooghe M.B., Haentjens P, Nagels G., D'Hooghe T, De Keyser J. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. J Neurol 2012; 259:855-861.
14. Correale J, Farez MF, Ysrraelit MC Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 2012; 72:682-694.
15. Tomassini V, Pozzilli C. Sex hormones: a role in the control of multiple sclerosis. Expert Opin Pharmacother 2006; 7:857-868.
16. McDonald WI, Compston A, Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-127.
17. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
18. Barkhof F, Simon JH, Fazekas F, et al MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol 2011; 8:13-21.
19. Morales LB, Loo KK, Liu H.B., Peterson C., Tiwari-Woodruff S, Voskuhl RR. Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci 2006; 26:6823-6833.
20. Matejuk A, Bakke AC, Hopke C, Dwyer J., Vandenbark AA, Offner H. Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. J Neurosci Res 2004; 77:119-126.
21. Zorgdrager A, De Keyser J. Menstrually related worsening of symptoms in multiple sclerosis. J Neurol Sci 1997; 149: 95-97.
22. Bebo BF J.r., Fyfe-Johnson A, Adlard K., Beam AG, Vandenbark AA, Offner H. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol 2001; 166:2080-2089.
23. Subramanian S, Matejuk A, Zamora A., Vandenbark AA, Offner H. Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J Immunol 2003; 170:1548-1555.
24. Bansil S, Lee HJ, Jindal S, Holtz C.R., Cook SD. Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis. Acta Neurol Scand 1999; 99:91-94.
25. Pozzilli C, Falaschi P, Mainero C., et al. MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns. Neurology 1999; 53:622-624.
26. Hall GM, Daniels M, Huskisson E.C., Spector TD. A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 1994; 53: 112-116.
27. De Cicco Nardone F, Rossiello F, Iacopino F, et al. Effects of interferon-beta on steroid receptors, prostaglandins and enzymatic activities in human endometrial cancer. Anticancer Res 1996; 16:161-169.
28. Barak V, Kalickman I, Nisman B., et al. Changes in cytokine production of breast cancer patients treated with interferons. Cytokine 1998; 10:977-983.
29. Reid R; Society of Obstetrician and Gynaecologists of Canada. SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update. J Obstet Gynaecol Can 2010; 32:1192-1204.